Boston Scientific Corporation $BSX Shares Bought by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 18.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,079,342 shares of the medical equipment provider’s stock after buying an additional 169,181 shares during the quarter. Boston Scientific accounts for 0.6% of UniSuper Management Pty Ltd’s portfolio, making the stock its 23rd biggest holding. UniSuper Management Pty Ltd’s holdings in Boston Scientific were worth $105,376,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in BSX. Norges Bank purchased a new position in Boston Scientific in the second quarter valued at about $2,089,937,000. Edgewood Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $746,655,000. Parnassus Investments LLC grew its holdings in shares of Boston Scientific by 42,978.9% in the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after acquiring an additional 6,868,459 shares during the period. Bessemer Group Inc. increased its stake in Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after purchasing an additional 2,899,653 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Boston Scientific by 133.5% during the third quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 93,095 shares of company stock valued at $9,305,450. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $92.56 on Friday. The stock’s fifty day simple moving average is $95.70 and its 200-day simple moving average is $99.87. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The stock has a market capitalization of $137.22 billion, a price-to-earnings ratio of 49.50, a price-to-earnings-growth ratio of 1.62 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period last year, the company earned $0.63 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Robert W. Baird raised their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Leerink Partners lifted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Oppenheimer lowered their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Finally, UBS Group reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $123.89.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.